Altamira Therapeutics Ltd. Profit Loss From Discontinued Operations
Altamira Therapeutics Ltd. (CYTOF) reported Profit Loss From Discontinued Operations of CHF 3.40 million for the 12-month period ending 2023-12-31, per its 20-F/A filed 2024-04-22.
Financial Statements › Notes
ifrs-full:ProfitLossFromDiscontinuedOperations · last filed 2025-04-30
CHF
| Period end | Profit Loss From Discontinued Operations 12 month |
|---|---|
| 2023-12-31 | 3.40M CHF 20-F/A · filed 2024-04-22 |
| 2022-12-31 | -7.88M CHF 20-F/A · filed 2024-04-22 |
| 2021-12-31 | -10.37M CHF 20-F/A · filed 2024-04-22 |
USD
| Period end | Profit Loss From Discontinued Operations 6 month | Profit Loss From Discontinued Operations 12 month |
|---|---|---|
| 2023-12-31 | $3.79M 20-F · filed 2025-04-30 | |
| 2023-06-30 | -$1.42M 6-K · filed 2024-09-24 | |
| 2022-12-31 | -$8.25M 20-F · filed 2025-04-30 |